Regulation
CorVista wins FDA clearance for AI heart failure assessment add-on
CorVista received FDA clearance for an AI-based pulmonary capillary wedge pressure assessment add-on for heart failure evaluation. This marks the company's third FDA clearance for its cardiopulmonary platform, expanding its diagnostic software capabilities in cardiac assessment.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network